Flerie’s portfolio company Empros Pharma reports study results positioning EMP16 as a promising oral weight-loss maintenance therapy
Flerie AB’s (publ) portfolio company Empros Pharma has announced data from its dose-escalation study, POEM, showing improved tolerability in patients taking EMP16 with dietary support. Along with the strong efficacy results from their Phase 2 program, these tolerability findings position EMP16 as a promising therapy for weight-loss maintenance.
“The treatment of obesity and overweight is undergoing a transformation, and it’s increasingly clear that we need a broad range of medications and therapies to help people not only lose weight, but most importantly, maintain their ideal weight long-term. We are very pleased that the POEM study results confirm EMP16’s potential as a long-term treatment and look forward to the continued progress and development,” says Mark Quick, Partner at Flerie.
Read Empros Pharma’s full press release here: https://emprospharma.com/topline-poem-study-results-position-emp16-as-a-promising-oral-weight-loss-maintenance-therapy/
Flerie’s holding in Empros Pharma amounts to 79%.
For more information:
Mark Quick, Partner
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com